Real-world evidence of long-term survival and healthcare resource use in patients with hepatic encephalopathy receiving rifaximin-α treatment: a retrospective observational extension study with long-term follow-up (IMPRESS II)Richard Aspinall, Debbie L. Shawcross, Elizabeth Farrington et al.|Frontline Gastroenterology|2022Cited by 5
P054 Long term survival and healthcare resource use in patients with hepatic encephalopathy receiving rifaximin-α treatment: a retrospective observational extension study with long term follow-up (IMPRESS II)Mark Hudson, Richard Aspinall, Stephen Ryder et al.|Unknown|2021Cited by 0